August 23, 2016
Valeant Pharmaceuticals International, Inc. (Laval, Quebec, Canada) announced that Paul S. Herendeen has been appointed Executive Vice President, Finance and will take over the role of Chief Financial Officer from Robert L. Rosiello, effective immediately. Mr. Herendeen joins Valeant from animal health company Zoetis (Florham Park, NJ), where he served as Executive Vice President and CFO for the past two years. Mr. Rosiello will remain at Valeant as Executive Vice President, Corporate Development and Strategy.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.